Diabetic Nephropathies (Diabetic Nephropathy)

Subscribe to Selected New Research on Diabetic Nephropathies

4563 relevant articles (256 outcomes, 745 trials/studies) found for this Disease

Description: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.

Also Known As:

Diabetic Nephropathy; Nephropathy, Diabetic; Diabetic Kidney Disease; Intracapillary Glomerulosclerosis; Kimmelstiel-Wilson Disease; Kimmelstiel-Wilson Syndrome; Nodular Glomerulosclerosis; Diabetic Kidney Diseases; Glomerulosclerosis, Nodular; Kidney Disease, Diabetic; Kidney Diseases, Diabetic; Kimmelstiel Wilson Disease; Kimmelstiel Wilson Syndrome; Nephropathies, Diabetic; Syndrome, Kimmelstiel-Wilson; Diabetic Glomerulosclerosis; Glomerulosclerosis, Diabetic

Relationship Network

Disease Context: Research Results

Male Urogenital Diseases

Urologic Diseases: 379

Kidney Diseases: 4235

Diabetic Nephropathies: 4563

Female Urogenital Diseases and Pregnancy Complications

Female Urogenital Diseases

Urologic Diseases: 379

Kidney Diseases: 4235

Diabetic Nephropathies: 4563

Endocrine System Diseases: 390

Diabetes Mellitus: 22586

Diabetes Complications: 2235

Diabetic Nephropathies: 4563

Related Diseases

1.	Hypertension (High Blood Pressure)
2.	Proteinuria
3.	Heart Failure
4.	Albuminuria
5.	Chronic Kidney Failure (Chronic Renal Failure)
253 Diseases and 1830 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Experts

1.	Parving, Hans-Henrik: 24 articles (09/2008 - 07/2002)
2.	Tarnow, Lise: 16 articles (09/2008 - 07/2002)
3.	Gilbert, Richard E: 13 articles (04/2008 - 06/2002)
4.	Cooper, Mark E: 13 articles (02/2008 - 03/2002)
5.	Kelly, Darren J: 13 articles (08/2007 - 03/2002)
6.	Tomino, Yasuhiko: 13 articles (02/2007 - 01/2002)
7.	Tarnow, L: 12 articles (07/2008 - 02/2000)
8.	Makino, Hirofumi: 12 articles (04/2008 - 01/2002)
9.	Rossing, Peter: 11 articles (09/2008 - 07/2002)
10.	Andersen, Steen: 10 articles (01/2006 - 07/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Diabetic Nephropathies:

1.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/01/1993 - "Strict glycemic control, and ACE inhibitors may be beneficial in early stages of diabetic nephropathy" 01/01/2005 - "CONCLUSION: As in other causes of non-diabetic kidney disease, antihypertensive regimens with ACE inhibitors are more effective in lowering urine protein excretion in patients with advanced PKD compared to regimens without ACE inhibitors, and this benefit is greater in patients with higher levels of baseline urine protein excretion" 01/01/2003 - "OBJECTIVE: ACE inhibitors are known to be effective in preventing the progression of diabetic nephropathy" 07/01/2001 - "The two main treatment strategies for primary prevention of diabetic nephropathy are improved glycaemic control and blood pressure lowering, particularly using drugs such as angiotensin-converting enzyme inhibitors" 09/01/1989 - "The relative superiority of ACE inhibitors in slowing the progression of chronic parenchymal renal disease remains to be demonstrated, although promising results have been reported in patients with diabetic nephropathy." Get all the results and reference details, order at left...
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 03/01/1995 - "In patients with diabetic nephropathy, angiotensin converting enzyme (ACE) inhibition has been shown to be more effective in this regard than conventional antihypertensive therapy" 09/07/1996 - "OBJECTIVE: To evaluate the concept that an insertion/deletion polymorphism of the angiotensin converting enzyme gene predicts the therapeutic efficacy of inhibition of angiotensin converting enzyme on progression of diabetic nephropathy" 04/01/1992 - "Angiotensin converting enzyme (ACE) inhibition has shown promising results in diabetic nephropathy, but long-term results on survival are not available" 07/01/2001 - "It should be recalled that development of treatment modalities occurred in reverse order: in the early 1980s, antihypertensive treatment of diabetic nephropathy was introduced, and in the early 1990s, primary and secondary prevention with improved glycaemic control and angiotensin-converting enzyme inhibition" 05/01/2008 - "OBJECTIVE: Recent studies have suggested an association between a deletion variant of the angiotensin-converting enzyme (ACE) gene and diabetic nephropathy" Get all the results and reference details, order at left...
3.	Insulin (Novolin)FDA Link 12/01/2004 - "Type I insulin dependent diabetic patients aged 45 or less with severe diabetic nephropathy, without immediate life saving cardiovascular risk, highly motivated and well informed achieve the best results" 01/01/1993 - "To determine the mechanisms underlying diabetic nephropathy (DN) onset, a clinical and morphological study was initiated of 14 diabetics with insulin-dependent disease free of clinical renal manifestations" 06/01/2008 - "Our study shows that podocyte inability to respond to insulin and susceptibility to cell death may partially account for the decreased podocyte number seen in early diabetic nephropathy." 02/01/2001 - "The present study was designed to evaluate the RAS in non-insulin dependent diabetic patients with diabetic nephropathy" 01/01/1997 - "However, long-term studies are needed to consolidate these findings and expand them to insulin-dependent diabetic patients with diabetic kidney disease." Get all the results and reference details, order at left...
4.	Angiotensin IIIBA 11/13/2008 - "The study also implicates that angiotensin II (AngII)-Src-Smad1 signaling pathway has played a key role for development of diabetic nephropathy" 01/01/2006 - "These and other studies indicate that angiotensin II antagonists not only improve survival and quality of life of patients with diabetic nephropathy, but also have the potential to reduce the substantial healthcare burden associated with managing these patients" 07/01/2003 - "Lewis study has demonstrated renoprotective effect of ACE inhibitor in type-1 diabetic nephropathy, and RENAAL and IDNT has documented that of angiotensin II type-1 receptor blocker in type-2 diabetes" 01/01/1997 - "This and other indirect evidence from experimental animal studies suggest that the intrarenal concentration of angiotensin II may be increased as a result of increased synthesis and despite enhanced breakdown, that this peptide participates in the progression of diabetic nephropathy" 11/13/2008 - "Intensive glycemic control and inhibition of angiotensin II delay the onset and progression of diabetic nephropathy, in part, through prevention of overproduction of ROS" Get all the results and reference details, order at left...
5.	Angiotensin Receptors (Angiotensin II Receptor)IBA 08/01/2005 - "Recent clinical trials have supported the use of angiotensin II receptor antagonists in the treatment of diabetic nephropathy, resulting in the approval of new therapeutic indications in the US and Europe" 08/07/2004 - "Several studies have found that angiotensin-II receptor antagonists have a renoprotective effect in type 2 diabetics with diabetic nephropathy, independently of their antihypertensive effects" 03/01/2004 - "Recent clinical trials have supported the use of angiotensin II receptor antagonists in the treatment of diabetic nephropathy, resulting in the approval of new therapeutic indications in the United States and Europe" 08/01/2003 - "Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial." 04/01/2007 - "Effects of angiotensin II receptor antagonist on rat podocyte injury in early diabetic nephropathy]" Get all the results and reference details, order at left...
6.	Transforming Growth Factor beta (TGF-beta)IBA 05/01/1999 - "Rather, interception of the effects of TGF-beta seems to be an approach most likely to yield beneficial results in diabetic nephropathy." 01/01/2001 - "Nevertheless, it is hoped that further studies to elucidate the efficacy of novel interventions to intercept the activity of the renal TGF-beta system will prove useful for effectively halting the progression of diabetic nephropathy." 01/03/2003 - "Anti-TGF-beta regimens would be useful in the treatment of diabetic nephropathy." 11/01/2008 - "Efficacy of gene therapy for transforming growth factor-beta in progressive diabetic nephropathy." 02/01/2006 - "The objective of the present study was to evaluate the KK-A(y)/Ta mouse as a suitable model for type 2 diabetic nephropathy including pathological changes and immunohistochemical analyses of AGE and TGF-beta, compared with the non-diabetic BALB/cA mouse" Get all the results and reference details, order at left...
7.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/30/2007 - "We hypothesized that the vascular endothelial growth factor (VEGF) participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy because of the effect it has on VEGF" 04/23/2004 - "We hypothesized that VEGF participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy through its effect on VEGF" 02/01/2006 - "BACKGROUND: Antagonism of vascular endothelial growth factor (VEGF) has improved the outcome in experimental nephropathies of various origins, including diabetic nephropathy in a type 1 diabetic rat model and a type 2 diabetic mouse model" 12/01/2008 - "However, the promise shown in the animal studies has not carried over as convincingly into the realm of human studies, as some investigators find a negative or no relationship between VEGF and diabetic nephropathy, whereas others find a positive correlation between the two" 05/01/2006 - "Several studies have implicated the angiogenic cytokine vascular endothelial growth factor (VEGF) in the development of diabetic nephropathy, but no data are available about its local activity during human disease" Get all the results and reference details, order at left...
8.	AngiotensinsIBA 03/01/2008 - "Clinical trials have found angiotensin receptor blockers (ARBs) to be more beneficial than traditional antihypertensive therapy in patients with type 2 diabetic nephropathy (DN)" 08/01/2007 - "The alterations in the signal pathways discussed in this review give support to the observational studies and clinical assays, where metabolic and antihypertensive controls obtained with angiotensin-converting inhibitors have shown important and additive effect in the prevention of the beginning and progression of diabetic nephropathy" 08/01/2002 - "Recent studies in patients with type 2 diabetes indicate a significant delay in progression or development of diabetic nephropathy following blockade of the renin-angiotensin-aldosterone system with the use of angiotensin receptor antagonists" 01/01/2002 - "With the reports of recently completed trials examining the role of angiotensin receptor blockers (ARBs) in type 2 diabetic nephropathy, the question has arisen as to which agents are best to block the RAS in type 2 diabetes" 01/01/2002 - "These trials all had a common theme--that is, does an angiotensin receptor blocker (ARB) interfere with the natural history of diabetic nephropathy in a blood pressure-independent fashion" Get all the results and reference details, order at left...
9.	Losartan (Cozaar)FDA Link 01/01/2001 - "CONCLUSION: Antihypertensive treatment with losartan exerts a beneficial effect on UAE, a benchmark for measuring the efficacy of therapeutic interventions in diabetic nephropathy, by reducing BP and allowing better diabetes control" 12/01/2004 - "Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results." 08/07/2004 - "The RENAAL study demonstrated the clinical benefits of losartan in patients with DM type 2 and advanced diabetic nephropathy" 10/01/2002 - "a separate study, losartan was shown to reduce the risk for progression of renal disease in patients with type 2 diabetic nephropathy" 08/01/2002 - "CONCLUSION: Our study suggests that the optimal dose of losartan is 100 mg daily for renoprotection and blood pressure reduction in type 1 diabetic patients with diabetic nephropathy." Get all the results and reference details, order at left...
10.	Captopril (Capoten)FDA LinkGeneric 09/01/2002 - "We conclude that CR should be considered as the standard diagnostic criteria of RVH and may be helpful in predicting the beneficial impact of captopril treatment in hypertensive patients with diabetic nephropathy." 11/01/1999 - "The renoprotective effect of captopril on progression of diabetic nephropathy was demonstrated by the Collaborative Study Group Captopril Trial and might be independent of blood pressure" 07/01/1995 - "Thirty-five of 45 patients participating in a prospective randomized study evaluating the effect of captopril in preventing the development of diabetic nephropathy were included in the present study, 17 being treated with captopril, 18 left as untreated controls" 11/11/1993 - "The purpose of this study was to determine whether captopril has kidney-protecting properties independent of its effect on blood pressure in diabetic nephropathy" 06/01/2008 - "In conclusion, an aqueous extract of PR has relatively good inhibitory effects on STZ-induced diabetes with early diabetic nephropathy with a similar efficacy to an equal dose of captopril." Get all the results and reference details, order at left...
1064 Drugs and Important Bio-Agents and 4104 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Pancreas Transplantation 02/01/1995 - "Combined kidney and pancreas transplantation is a safe and effective treatment option for diabetic nephropathy" 05/01/2001 - "Resolution of renal lesions (62%) has been claimed in a single study and in a small number of patients with diabetic nephropathy after 10-year pancreas transplantation" 01/01/2007 - "Combined kidney-pancreas transplantation is the treatment of choice for end-stage diabetic nephropathy" 01/01/2007 - "Tight glycemic control can reduce progression of diabetic nephropathy (DN) while the histological changes may regress after pancreas transplantation" 01/01/2006 - "BACKGROUND: Combined kidney pancreas transplantation (PTx) evolved as excellent treatment for diabetic nephropathy" Get all the results and reference details, order at left...
2.	Kidney Transplantation 03/01/2004 - "Today, simultaneous pancreas and kidney transplantation is the gold standard procedure for end-stage type 1 diabetic nephropathy recipients." 06/01/1984 - "Improved results of renal transplantation in diabetic nephropathy." 09/01/2008 - "A 48-yr-old patient underwent combined retroperitoneal pancreas and kidney transplantation because of type-I-diabetes, and diabetic nephropathy" 09/01/2008 - "Patients 40 years or older, especially with diabetic nephropathy or nondiabetic disease, but a long expected waiting time for kidney transplantation, show better survival receiving an ECD kidney than remaining on dialysis therapy." 07/01/2005 - "Combined pancreas and kidney transplantation should be offered to patients with end-stage diabetic nephropathy." Get all the results and reference details, order at left...
3.	Protein-Restricted Diet (Diet, Protein Restricted) 08/01/2001 - "RESULTS AND CONCLUSIONS: Low and very low-protein diets associated with specific enteral supplements are indicated in most patients with chronic renal disease and in patients with incipient diabetic nephropathy to slow progression of disease and to improve their overall status, contributing to improved survival (grade A recommendation)" 02/01/2006 - "Reduction of urinary protein levels by various medications and a low-protein diet limits renal function decline in individuals with nondiabetic and diabetic nephropathies to the point that remission of the disease and regression of renal lesions have been observed in experimental animals and even in humans" 09/01/2008 - "Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials." 07/01/1993 - "This study was designed to clarify the mechanisms by which the progression of diabetic nephropathy is inhibited by low-protein diet" 09/01/2008 - "BACKGROUND: A low-protein diet (LPD) has been proposed for many years to delay the progression of diabetic nephropathy" Get all the results and reference details, order at left...
4.	Renal Dialysis (Hemodialysis) 01/01/2008 - "Therapeutic options such as strict blood pressure and/or glycemic control are effective for preventing the development and progression of diabetic nephropathy, but the number of diabetic patients on hemodialysis is still increasing" 02/01/2001 - "The purpose of this study is to clarify the role of diabetic nephropathy on outcomes of a group of patients on chronic hemodialysis undergoing CABG" 07/01/2008 - "OBJECTIVES: To evaluate the influence of hemodialysis on cardiovascular risk factors and on their frequency in diabetic nephropathy patients" 01/01/2008 - "CONCLUSION: Our data indicate that mortality of hemodialysis patients with type-2 diabetic nephropathy is influenced neither by dialyzer flux level nor by biocompatibility." 12/01/2006 - "A 64-year-old male patient with diabetic nephropathy had been treated with maintenance hemodialysis therapy for 4 years, and had developed disturbed consciousness" Get all the results and reference details, order at left...
5.	Transplants (Transplant) 02/01/1990 - "While a renal graft allows improved detection of pancreas rejection, a pancreatic graft confers protection against recurrence of diabetic nephropathy" 11/01/2007 - "We speculate that long exposure to smoking may be the etiologic factor for nodular glomerulosclerosis in the kidney graft of our patient" 05/01/2007 - "Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy." 04/01/2007 - "MATERIALS AND METHODS: The outcomes of 56 transplant patients (58 grafts) with biopsy-proven IgAN and of 116 patients without IgAN or diabetic nephropathy, transplanted during the same period were analyzed" 01/01/2007 - "The use of both types of composite organ transplants may eventually be applicable to the treatment of type I diabetic patients suffering from end-stage diabetic nephropathy." Get all the results and reference details, order at left...
69 Therapies and Procedures and 641 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician
Research Summary Report
on Diabetic Nephropathies

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 256 Outcomes
Top 200 Key Medications
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>